Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Core Insights - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on immunotherapy for oncology, specifically developing pelareorep, which has shown promising results in treating metastatic breast cancer and pancreatic cancer [5][6]. Group 1: Company Overview - Oncolytics Biotech Inc. specializes in developing pelareorep, an intravenously delivered immunotherapeutic agent that induces anti-cancer immune responses [5]. - Pelareorep has demonstrated efficacy in two randomized Phase 2 studies for metastatic breast cancer and Phase 1 and 2 studies for pancreatic cancer [5]. - The company is advancing towards registrational studies in both metastatic breast cancer and pancreatic cancer, which have received Fast Track Designation from the FDA [6]. Group 2: Treatment Innovations - Key opinion leaders discussed the need for new treatment innovations in oncology, particularly for HR+/HER2- metastatic breast cancer, highlighting pelareorep's potential to activate the immune system [2]. - Insights were provided on the treatment of pancreatic ductal adenocarcinoma (PDAC), emphasizing the resistance of this cancer type to current treatments and the potential impact of immunotherapy like pelareorep [3]. Group 3: Clinical Trials and Synergies - Oncolytics is conducting and planning combination clinical trials with pelareorep in solid malignancies, indicating a strategic approach to enhance treatment efficacy [6]. - Pelareorep has shown synergies with multiple approved oncology treatments, suggesting its potential to be integrated into existing therapeutic regimens [6].